New technologies in the complex therapy of peptic ulcer disease duodenum
AUTHORS : Khachumova K.G. | Leontyev N.V.
RELEVANT UNIVERSITIES : GOU VPO RNIMU named after N.I. Pirogov, Moscow, Russia
YEAR : 2014
The treatment of peptic ulcer disease remains a challenge for doctors. The presence of Helicobacter pylori is considered the most important
etiopathogenetic factor in the development of gastric ulcer and duodenal ulcer (DU) [6, 10]. The lack of schemes that guarantee 100% success makes
researchers look for new ways to solve this problem. The largest number of meta-analyzes are devoted to assessing the effectiveness of first-line therapy
regimens, which traditionally include a proton pump inhibitor, clarithromycin, and amoxicillin (or metronidazole) [7, 9]. If in the mid-90s of the last century
the efficiency of this scheme was 90%, now in many regions of the world it rarely exceeds 60% [10]. The results of numerous studies by foreign and
domestic authors have shown a high therapeutic activity of omeprazole, a proton pump blocker in the treatment of DU. The activity of therapy with
omeprazole on the acid-producing function of the stomach, the state of the mucous membrane of the stomach, duodenum and the degree of
contamination of Helicobacter pylori has been proven [1, 4]. However